Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 versus RENO 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 versus RENO 30.
IOPAMIDOL-200 vs RENO-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It does not have a pharmacological effect but provides radiographic opacity.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
Intravascular: 50-150 mL (75-225 mg iodine/kg) IV; frequency depends on procedure, usually single dose. Intrathecal: 5-15 mL (200 mg iodine/mL) injected into subarachnoid space.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
None Documented
None Documented
Terminal half-life: 2 hours (normal renal function); prolonged to 8-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: >95% unchanged via glomerular filtration within 24 hours; biliary/fecal: <1%.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent